Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Diffuse large B-cell lymphomas (DLBCLs) are phenotypically and genetically heterogeneous. Gene-expression profiling has identified subgroups of DLBCL (activated B-cell-like [ABC], germinal-center B-cell-like [GCB], and unclassified) according to cell of origin that are associated with a differential response to chemotherapy and targeted agents. We sought to extend these findings by identifying genetic subtypes of DLBCL based on shared genomic abnormalities and to uncover therapeutic vulnerabilities based on tumor genetics. METHODS: We studied 574 DLBCL biopsy samples using exome and transcriptome sequencing, array-based DNA copy-number analysis, and targeted amplicon resequencing of 372 genes to identify genes with recurrent aberrations. We developed and implemented an algorithm to discover genetic subtypes based on the co-occurrence of genetic alterations. RESULTS: and CD79B mutations), BN2 (based on BCL6 fusions and NOTCH2 mutations), N1 (based on NOTCH1 mutations), and EZB (based on EZH2 mutations and BCL2 translocations). Genetic aberrations in multiple genes distinguished each genetic subtype from other DLBCLs. These subtypes differed phenotypically, as judged by differences in gene-expression signatures and responses to immunochemotherapy, with favorable survival in the BN2 and EZB subtypes and inferior outcomes in the MCD and N1 subtypes. Analysis of genetic pathways suggested that MCD and BN2 DLBCLs rely on "chronic active" B-cell receptor signaling that is amenable to therapeutic inhibition. CONCLUSIONS: We uncovered genetic subtypes of DLBCL with distinct genotypic, epigenetic, and clinical characteristics, providing a potential nosology for precision-medicine strategies in DLBCL. (Funded by the Intramural Research Program of the National Institutes of Health and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“LBCL is genetically and biologically heterogeneous. This diversity includes both tumor and the corresponding tumor microenvironment (TME), and it affects response to standard immunochemotherapy.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Self-citationRosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
Self-citationStromal Gene Signatures in Large-B-Cell Lymphomas
Lenz, G., Wright, G., Dave, S. S., Xiao, W., Powell, J., Zhao, H., Xu, W., Tan, B., Goldschmidt, N., Iqbal, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802885 · Cited by 1,808
Self-citationChronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
Davis, R. E., Ngo, V. N., Lenz, G., Tolar, P., Young, R. M., Romesser, P. B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., et al. (2010) · Nature · doi:10.1038/nature08638 · Cited by 1,643
Self-citationOncogenically active MYD88 mutations in human lymphoma
Ngo, V. N., Young, R. M., Schmitz, R., Jhavar, S., Xiao, W., Lim, K.-H., Kohlhammer, H., Xu, W., Yang, Y., Zhao, H., et al. (2011) · Nature · doi:10.1038/nature09671 · Cited by 1,512
Self-citationTargeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wilson, W. H., Young, R. M., Schmitz, R., Yang, Y., Pittaluga, S., Wright, G., Lih, C.-J., Williams, P. M., Shaffer, A. L., Gerecitano, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3884 · Cited by 1,113
Self-citationA loss-of-function RNA interference screen for molecular targets in cancer
Ngo, V. N., Davis, R. E., Lamy, L., Yu, X., Zhao, H., Lenz, G., Lam, L. T., Dave, S., Yang, L., Powell, J., et al. (2006) · Nature · doi:10.1038/nature04687 · Cited by 605
Self-citationExploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma
Yang, Y., Shaffer, A. L., Emre, N. C. T., Ceribelli, M., Zhang, M., Wright, G., Xiao, W., Powell, J., Platig, J., Kohlhammer, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.024 · Cited by 521
Self-citationInhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma
Lionakis, M. S., Dunleavy, K., Roschewski, M., Widemann, B. C., Butman, J. A., Schmitz, R., Yang, Y., Cole, D. E., Melani, C., Higham, C. S., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.012 · Cited by 508
Self-citationChalla-Malladi, M., Lieu, Y. K., Califano, O., Holmes, A. B., Bhagat, G., Murty, V. V., Dominguez-Sola, D., Pasqualucci, L., & Dalla-Favera, R. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.006 · Cited by 439
Cited by
Items 501–600 of 1,000
Shanmugam, V., Craig, J. W., Hilton, L. K., Nguyen, M. H., Rushton, C. K., Fahimdanesh, K., Lovitch, S. B., Ferland, B., Scott, D. W., & Aster, J. C. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020002995 · Cited by 28
Genetics of Diffuse Large B-Cell Lymphoma.
Wright, G. W., Wilson, W. H., & Staudt, L. M. (2018) · PubMed · doi:10.1056/nejmc1806191 · Cited by 27
Self-citationSequencing of Anti-CD19 Therapies in the Management of Diffuse Large B-Cell Lymphoma
Lownik, J. C., Boiarsky, J., Birhiray, R. E., Merchant, A. A., & Mead, M. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1962 · Cited by 27
Chen, S., Xu, P., Feng, R., Cui, G., Wang, L., Cheng, S., Mu, R., Zhang, H., Wei, X., Song, Y., et al. (2025) · 癌症:英文版 · doi:10.1002/cac2.70033 · Cited by 27
Non-Hodgkin Lymphomas: Malignancies Arising from Mature B Cells
Shingleton, J. R., Wang, J., Baloh, C., Dave, T., Davis, N. S., Happ, L. E., Jadi, O., Kositsky, R., Li, X., Love, C., et al. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a034843 · Cited by 27
Self-citationIbrutinib in B-cell lymphoma: single fighter might be enough?
Xue, C., Wang, X., Zhang, L., Qu, Q., Zhang, Q., & Jiang, Y. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01518-y · Cited by 27
A prognostic index predicting survival in transformed Waldenström macroglobulinemia
Durot, É., Kanagaratnam, L., Zanwar, S., Kastritis, E., D’Sa, S., García‐Sánz, R., Tomowiak, C., Hivert, B., Toussaint, E., Protin, C. A., et al. (2020) · Haematologica · doi:10.3324/haematol.2020.262899 · Cited by 27
Roberto, M. P., Varano, G., Viñas-Castells, R., Holmes, A. B., Kumar, R., Pasqualucci, L., Farinha, P., Scott, D. W., & Dominguez-Sola, D. (2021) · Immunity · doi:10.1016/j.immuni.2021.07.009 · Cited by 27
Laurent, C., Syrykh, C., Hamon, M., Adélaïde, J., Guillé, A., Escudié, F., Jalowicki, G., Fina, F., Bardet, A., Mescam, L., et al. (2021) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001834 · Cited by 27
Zanelli, M., Sanguedolce, F., Zizzo, M., Palicelli, A., Pellegrini, D., Farinacci, S., Soriano, A., Froio, E., Cormio, L., Carrieri, G., et al. (2022) · Current Oncology · doi:10.3390/curroncol29020081 · Cited by 27
Deep phenotyping for precision medicine in Parkinson's disease
Schalkamp, A., Rahman, N., Monzón‐Sandoval, J., & Sandor, C. (2022) · Disease Models & Mechanisms · doi:10.1242/dmm.049376 · Cited by 27
Diffuse large B-cell lymphoma and new insights into its pathobiology and implication in treatment
Mamgain, G., Singh, P. K., Patra, P., Naithani, M., & Nath, U. K. (2022) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_2432_21 · Cited by 27
TBL1X: At the crossroads of transcriptional and posttranscriptional regulation
Pray, B. A., Youssef, Y., & Alinari, L. (2022) · Experimental Hematology · doi:10.1016/j.exphem.2022.09.006 · Cited by 27
An Aged/Autoimmune B-cell Program Defines the Early Transformation of Extranodal Lymphomas
Venturutti, L., Rivas, M. A., Pelzer, B. W., Flümann, R., Hansen, J., Karagiannidis, I., Xia, M., McNally, D. R., Isshiki, Y., Lytle, A. G., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0561 · Cited by 27
Shen, J., & Liu, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1034668 · Cited by 27
Diffuse large B-cell lymphomas, not otherwise specified, and emerging entities
Song, J. Y., Dirnhofer, S., Piris, M. A., Quintanilla‐Martínez, L., Pileri, S. A., & Campo, E. (2022) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-022-03466-6 · Cited by 27
Self-citationGenetic Profiling in Diffuse Large B-Cell Lymphoma: The Promise and the Challenge
Cutmore, N. H., Krupka, J. A., & Hodson, D. J. (2023) · Modern Pathology · doi:10.1016/j.modpat.2022.100007 · Cited by 27
Self-citationTranscriptional reprogramming by mutated IRF4 in lymphoma
Schleußner, N., Cauchy, P., Franke, V., Giefing, M., Fornés, O., Vankadari, N., Assi, S. A., Costanza, M., Weniger, M. A., Akalin, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41954-8 · Cited by 27
Self-citationAdvances in pathological understanding of high-grade B cell lymphomas
Li, S., Lin, P., & Medeiros, L. J. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1494567 · Cited by 27
High-grade B-cell lymphoma: how to diagnose and treat
Novo, M., Castellino, A., Nicolosi, M., Santambrogio, E., Vassallo, F., Chiappella, A., & Vitolo, U. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1624157 · Cited by 27
Xiu, Y., Dong, Q., Fu, L., Bossler, A., Tang, X., Boyce, B. F., Borcherding, N. C., Leidinger, M., Sardina, J. L., Xue, H., et al. (2019) · Blood · doi:10.1182/blood.2019001438 · Cited by 27
Della-Valle, V., Roos‐Weil, D., Scourzic, L., Mouly, E., Aid, Z., Darwiche, W., Lécluse, Y., Damm, F., Mémet, S., Mercher, T., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0305-6 · Cited by 27
Epigenetic Mechanisms of Therapy Resistance in Diffuse Large B Cell Lymphoma (DLBCL)
Isshiki, Y., & Melnick, A. M. (2021) · Current Cancer Drug Targets · doi:10.2174/1568009620666210106122750 · Cited by 27
Ghesquières, H., Rossi, C., Cherblanc, F., Guyader-Peyrou, S. L., Bijou, F. D., Sujobert, P., Fabbro-Péray, P., Bernier, A., Belot, A., Chartier, L., et al. (2021) · BMC Public Health · doi:10.1186/s12889-021-10433-4 · Cited by 27
Xu, C., Bulusu, K. C., Pan, H., & Elemento, O. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.06.627266 · Cited by 27
Laurent, C., Trisal, P., Tesson, B. M., Seth, S., Beyou, A., Roulland, S., Lesne, B., Acker, N. V., Cerapio, J., Chartier, L., et al. (2024) · Blood · doi:10.1182/blood.2024024496 · Cited by 26
Self-citationGăman, M., Epîngeac, M. E., & Găman, A. M. (2019) · Revista de Chimie · doi:10.37358/rc.19.3.7043 · Cited by 26
Chen, F., Pang, D., Guo, H., Jiang, X., Liu, S., Huang, L., Wei, X., Liang, Z., Wang, X., & Li, W. (2020) · Cancer Management and Research · doi:10.2147/cmar.s242903 · Cited by 26
Taking the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomas
Morschhauser, F., Salles, G. A., Batlevi, C. L., Tilly, H., Chaidos, A., Phillips, T., Burke, J. M., & Melnick, A. M. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.100988 · Cited by 26
A 9-LncRNA Signature for Predicting Prognosis and Immune Response in Diffuse Large B-Cell Lymphoma
Wang, X., Lu, Y., Liu, Z., Zhang, Y., He, Y., Sun, C., Li, L., Zhai, Q.-L., Meng, B., Ren, X., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.813031 · Cited by 26
Novel eIF4A1 inhibitors with anti‐tumor activity in lymphoma
Kayastha, F. B., Herrington, N. B., Kapadia, B. B., Roychowdhury, A., Nanaji, N. M., Kellogg, G. E., & Gartenhaus, R. B. (2022) · Molecular Medicine · doi:10.1186/s10020-022-00534-0 · Cited by 26
Vlasevska, S., Garcia‐Ibanez, L., Duval, R., Holmes, A. B., Jahan, R., Bowen, C., Kim, A. H., Mo, T., Basso, K., Soni, R. K., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2218330120 · Cited by 26
A genetic profiling guideline to support diagnosis and clinical management of lymphomas
Sánchez‐Beato, M., Méndez, M., Guirado, M., Pedrosa, L., Sequero, S., Yanguas‐Casás, N., de la Cruz‐Merino, L., Gálvez, L., Llanos, M., García, J. F., et al. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03307-1 · Cited by 26
The current landscape of frontline large B-cell lymphoma trials
Qualls, D. A., Armand, P. A., & Salles, G. A. (2024) · Blood · doi:10.1182/blood.2023023789 · Cited by 26
Sequencing of therapy for patients with diffuse large B‐cell lymphoma in the era of novel drugs
Karsten, I. E., Shumilov, E., Schmitz, N., & Lenz, G. (2024) · British Journal of Haematology · doi:10.1111/bjh.19860 · Cited by 26
Kim, D. J., Kim, T., Jeong, J., Jo, J., Lee, W. S., Shin, H., Lee, J. H., & Lee, H. S. (2020) · International Journal of Hematology · doi:10.1007/s12185-019-02816-6 · Cited by 26
Molecular profiling of Chinese R‐CHOP treated DLBCL patients: Identifying a high‐risk subgroup
Jiang, S., Qin, Y., Jiang, H., Liu, B., Shi, J., Meng, F., Liu, P., Yang, J., Yang, S., He, X., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33049 · Cited by 26
Role of Microenvironment in Non-Hodgkin Lymphoma: Understanding the Composition and Biology
Khurana, A., & Ansell, S. M. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000446 · Cited by 26
Xu, Y.-Z., Jenjaroenpun, P., Wongsurawat, T., Byrum, S. D., Shponka, V., Tannahill, D., Chavez, E. A., Hung, S. S., Steidl, C., Balasubramanian, S., et al. (2020) · NAR Cancer · doi:10.1093/narcan/zcaa029 · Cited by 26
Self-citationTong, K. I., Yoon, S., Isaev, K., Bakhtiari, M., Lackraj, T., He, M. Y., Joynt, J., Silva, A., Xu, M. C., Privé, G. G., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4027 · Cited by 26
Molecular Update and Evolving Classification of Large B-Cell Lymphoma
Onaindía, A., Santiago-Quispe, N., Martínez, E. I., & Abrio, C. R. (2021) · Cancers · doi:10.3390/cancers13133352 · Cited by 26
Qin, Y., & #x0026 (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2021.0193 · Cited by 26
Super enhancers as master gene regulators in the pathogenesis of hematologic malignancies
Debek, S. M., & Juszczyński, P. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188697 · Cited by 26
Takata, K., Chong, L. C., Ennishi, D., Aoki, T., Li, M. Y., Thakur, A., Healy, S., Viganò, E., Dao, T., Kwon, D., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci145343 · Cited by 26
Self-citationQiu, Z., Khalife, J., Ethiraj, P., Jaafar, C., Lin, A.-P., Holder, K. N., Ritter, J. P., Chiou, L., Huelgas-Morales, G., Aslam, S., et al. (2024) · Science Advances · doi:10.1126/sciadv.adk2091 · Cited by 25
Somatic genetic aberrations in benign breast disease and the risk of subsequent breast cancer
Zeng, Z., Vo, A. H., Li, X., Shidfar, A., Saldana, P., Blanco, L. Z., Xuei, X., Luo, Y., Khan, S. A., & Clare, S. E. (2020) · npj Breast Cancer · doi:10.1038/s41523-020-0165-z · Cited by 25
Han, B., Kim, S., Koh, J., Yim, J., Lee, C., Heo, D. S., Kim, T. M., Paik, J. H., & Jeon, Y. K. (2020) · Cancers · doi:10.3390/cancers12113305 · Cited by 25
Allegra, A., Pioggia, G., Innao, V., Musolino, C., & Gangemi, S. (2021) · Cancers · doi:10.3390/cancers13081981 · Cited by 25
Sun, Y.-C., Gao, Y., Chen, J., Huang, L., Deng, P., Chen, J., Chai, K. X. Y., Hong, J. H., Chan, J. Y., He, H., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.09.002 · Cited by 25
Self-citationMondello, P., Ansell, S. M., & Nowakowski, G. S. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.826594 · Cited by 25
Gu, J., Jiang, T., Liu, S., Ping, B., Li, R., Chen, W., Wang, L., Huang, X., Xu, G., & Chang, Q. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.932674 · Cited by 25
Primary Vitreoretinal Lymphoma: Current Diagnostic Laboratory Tests and New Emerging Molecular Tools
Melli, B., Gentile, P., Nicoli, D., Farnetti, E., Croci, S., Gozzi, F., Bolletta, E., Simone, L. D., Sanguedolce, F., Palicelli, A., et al. (2022) · Current Oncology · doi:10.3390/curroncol29100543 · Cited by 25
Rizzello, C., Cancila, V., Sangaletti, S., Botti, L., Ratti, C., Milani, M., Dugo, M., Bertoni, F., Tripodo, C., Chiodoni, C., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01687-6 · Cited by 25
CNS prophylaxis in aggressive B-cell lymphoma
Wilson, M. R., Bobillo, S., & Cwynarski, K. (2022) · Hematology · doi:10.1182/hematology.2022000331 · Cited by 25
Unraveling the genetics of transformed splenic marginal zone lymphoma
Grau, M., López, C., Navarro, A., Frigola, G., Nadeu, F., Clot, G., Bastidas, G., Alcoceba, M., Baptista, M. J., Blanes, M., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009415 · Cited by 25
Self-citationChen, X., Li, Y., Zhu, F., Xu, X., Estrella, B., Pazos, M. A., McGuire, J. T., Karagiannis, D., Sahu, V., Mustafokulov, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39990-5 · Cited by 25
Leveraging altered lipid metabolism in treating B cell malignancies
Lee, J. W., Mani, A., Shin, M., & Krauss, R. M. (2024) · Progress in Lipid Research · doi:10.1016/j.plipres.2024.101288 · Cited by 25
Stokes, M. E., Wenzl, K., Huang, C. C., Ortiz, M., Hsu, C.-C., Maurer, M. J., Stong, N., Nakayama, Y., Wu, L., Chiu, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50830-y · Cited by 25
The role of aurora A and polo-like kinases in high-risk lymphomas
Murga‐Zamalloa, C., Inamdar, K. V., & Wilcox, R. A. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000232 · Cited by 25
Abramson, J. S. (2019) · Cancer · doi:10.1002/cncr.32145 · Cited by 25
Targeting Notch Trafficking and Processing in Cancers
Pagliaro, L., Sorrentino, C., & Roti, G. (2020) · Cells · doi:10.3390/cells9102212 · Cited by 25
Hodkinson, B. P., Schäffer, M., Brody, J., Jurczak, W. J., Carpio, C. D. C., Ben‐Yehuda, D., Avivi, I. M., Forslund, A., Özcan, M., Alvarez, J. D., et al. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100977 · Cited by 25
Cost burden of diffuse large B-cell lymphoma
Harkins, R. A., Patel, S. P., & Flowers, C. R. (2019) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2019.1680288 · Cited by 25
Stelling, A., Wu, C. T., Bertram, K., Hashwah, H., Theocharides, A. P. A., Manz, M. G., Tzankov, A., & Mueller, A. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000210 · Cited by 25
Genomic landscape of virus-associated cancers
Gomez, K., Schiavoni, G., Nam, Y., Reynier, J.-B., Khamnei, C., Aitken, M., Palmieri, G., Cossu, A., Levine, A., van Noesel, C. J. M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60836-9 · Cited by 24
Pharmacogenetics in diffuse large B-cell lymphoma treated with R-CHOP: Still an unmet challenge
Lavacchi, D., Landini, I., Perrone, G., Roviello, G., Mini, E., & Nobili, S. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107924 · Cited by 24
The RNA regulatory programs that govern lymphocyte development and function
Díaz‐Muñoz, M. D., & Osma-García, I. C. (2021) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1683 · Cited by 24
Roh, J., Cho, H., Pak, H.-K., Lee, Y. S., Lee, S.-W., Ryu, J., Chae, E. J., Kim, K. W., Huh, J., Choi, Y. S., et al. (2021) · Modern Pathology · doi:10.1038/s41379-021-00962-z · Cited by 24
Pindzola, G. M., Razzaghi, R., Tavory, R. N., Nguyen, H. T. T., Morris, V. M., Li, M., Agarwal, S., Huang, B., Okada, T., Reinhardt, H. C., et al. (2022) · Blood · doi:10.1182/blood.2022015926 · Cited by 24
Self-citationRamchandren, R., Johnson, P., Ghosh, N., Ruan, J., Ardeshna, K. M., Johnson, R. J., Verhoef, G. E. G., Cunningham, D., de Vos, S., Kassam, S., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101779 · Cited by 24
Vries, G. T. L.-D., Stathi, P., Rutkens, R., Hijmering, N. J., Luijks, J. A. C. W., Groenen, P. J. T. A., de Jong, D., Ylstra, B., & Roemer, M. G. M. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3814 · Cited by 24
El‐Sharkawi, D., Sud, A., Prodger, C. F., Khwaja, J., Shotton, R., Hanley, B. P., Peacock, V., Peng, Y. Y., Arasaretnam, A., Sharma, S., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00827-5 · Cited by 24
Oxidative stress enhances the therapeutic action of a respiratory inhibitor in MYC‐driven lymphoma
Donati, G., Nicoli, P., Verrecchia, A., Vallelonga, V., Croci, O., Rodighiero, S., Audano, M., Cassina, L., Ghsein, A., Binelli, G., et al. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202216910 · Cited by 24
ADAR1-mediated RNA editing promotes B cell lymphomagenesis
Pecori, R., Ren, W., Pirmoradian, M., Wang, X., Liu, D., Berglund, M., Li, W., Tasakis, R. N., Giorgio, S. D., Ye, X., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106864 · Cited by 24
Xu-Monette, Z. Y., Li, Y., Snyder, T. M., Yu, T., Lu, T., Tzankov, A., Visco, C., Bhagat, G., Qian, W., Dybkær, K., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1554 · Cited by 24
Targeting MyD88: Therapeutic mechanisms and potential applications of the specific inhibitor ST2825
Liu, M., Kang, W., Hu, Z., Wang, C., & Zhang, Y. (2023) · Inflammation Research · doi:10.1007/s00011-023-01801-4 · Cited by 24
DLBCL arising from indolent lymphomas: How are they different?
Parry, E. M., Roulland, S., & Okosun, J. (2023) · Seminars in Hematology · doi:10.1053/j.seminhematol.2023.11.002 · Cited by 24
Self-citationMultiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL
Wenzl, K., Stokes, M. E., Novak, J. P., Bock, A. M., Khan, S., Hopper, M. A., Krull, J. E., Dropik, A. R., Walker, J. S., Sarangi, V., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01080-0 · Cited by 24
Self-citationMasnikosa, R., Cvetković, Z., & Pirić, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111384 · Cited by 24
Zhao, P., Zhao, S., Huang, C., Li, Y., Wang, J., Xu, J., Li, L., Qian, Z., Li, W., Zhou, S., et al. (2024) · Hematological Oncology · doi:10.1002/hon.70017 · Cited by 24
Self-citationThe Unsolved Puzzle of c-Rel in B Cell Lymphoma
Kober, M., & Schmidt‐Supprian, M. (2019) · Cancers · doi:10.3390/cancers11070941 · Cited by 24
Epigenetic Mechanisms in Leukemias and Lymphomas
Duy, C., Béguelin, W., & Melnick, A. M. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a034959 · Cited by 24
Thomsen, E. A., Rovsing, A. B., Anderson, M. V., Due, H., Huang, J., Luo, Y., Dybkær, K., & Mikkelsen, J. G. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12753 · Cited by 24
CCND1 Genomic Rearrangement as a Secondary Event in High Grade B-Cell Lymphoma
Cheng, J., Hashem, M. A., Barabé, F., Cloutier, S., Xi, L., Raffeld, M. A., Pittaluga, S., & Jaffe, E. S. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000505 · Cited by 24
Self-citationRituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways
Edelmann, J., Dokal, A. D., Vilventhraraja, E., Holzmann, K., Britton, D., Klymenko, T., Döhner, H., Cragg, M. S., Braun, A., Cutillas, P. R., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102089 · Cited by 24
Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study
Strati, P., de Vos, S., Ruan, J., Maddocks, K. J., Flowers, C. R., Rule, S. A., Patel, P. S., Xu, Y., Wei, H., Frigault, M. M., et al. (2021) · Haematologica · doi:10.3324/haematol.2021.278654 · Cited by 24
Miyawaki, K., Kato, K., Sugio, T., Sasaki, K., Miyoshi, H., Semba, Y., Kikushige, Y., Mori, Y., Kunisaki, Y., Iwasaki, H., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021004618 · Cited by 23
FCRL1 immunoregulation in B cell development and malignancy
Mamidi, M. K., Huang, J., Honjo, K., Li, R., Tabengwa, E. M., Neeli, I., Randall, N. L., Ponnuchetty, M. V., Radic, M. Z., Leu, C., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1251127 · Cited by 23
Cooper, A. B., Tumuluru, S., Kissick, K., Venkataraman, G., Song, J. Y., Lytle, A. G., Duns, G., Yu, J., Kotlov, N., Bagaev, A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.01574 · Cited by 23
Prinz, L. F., Riët, T., Neureuther, D. F., Lennartz, S., Chrobok, D., Hübbe, H., Uhl, G., Riet, N., Hofmann, P., Hösel, M., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101421 · Cited by 23
Ito, Y., Marouf, A., Kogure, Y., Koya, J., Liévin, R., Bruneau, J., Tabata, M., Saito, Y., Shingaki, S., Yuasa, M., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-0132 · Cited by 23
Li, M. Y., Chong, L. C., Duns, G., Lytle, A. G., Woolcock, B. W., Jiang, A., Telenius, A., Ben‐Neriah, S., Nawaz, W., Slack, G. W., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2320421121 · Cited by 23
Vaughn, J. L., Ramdhanny, A., Munir, M., Rimmalapudi, S., & Epperla, N. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01194-5 · Cited by 23
Mutational Evolution in Relapsed Diffuse Large B-Cell Lymphoma
Nijland, M., Seitz, A., Terpstra, M. M., Imhoff, G. W. V., Kluin, P. M., van Meerten, T., Atayar, Ç., van Kempen, L. C. L. T., Diepstra, A., Kok, K., et al. (2018) · Cancers · doi:10.3390/cancers10110459 · Cited by 23
Prognostic and Predictive Biomarkers in Diffuse Large B-cell Lymphoma
Chan, A., & Doǧan, A. (2019) · Surgical pathology clinics · doi:10.1016/j.path.2019.03.012 · Cited by 23
Elfrink, S., de Winde, C. M., van den Brand, M., Berendsen, M. R., Roemer, M. G. M., Arnold, F., Janssen, L., van der Schaaf, A., Jansen, E., Groenen, P. J. T. A., et al. (2019) · Blood · doi:10.1182/blood.2019001185 · Cited by 23
Hussein, S. E., Shaw, K. R. M., & Vega, F. (2020) · Modern Pathology · doi:10.1038/s41379-020-0616-y · Cited by 23
Prognostic Value of EZH2 in Non‐Small‐Cell Lung Cancers: A Meta‐Analysis and Bioinformatics Analysis
Fan, K., Zhang, C., Qi, Y., Dai, X., Birling, Y., Tan, Z., & Cao, F. (2020) · BioMed Research International · doi:10.1155/2020/2380124 · Cited by 23
Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas
Leeman‐Neill, R. J., Soderquist, C. R., Montanari, F., Raciti, P., Park, D. S., Radeski, D., MANSUKHANI, M. M., Murty, V. V. V. S., Hsiao, S. J., Alobeid, B., et al. (2020) · Haematologica · doi:10.3324/haematol.2020.267294 · Cited by 23
Tan, W. J., Wang, M. M., Ricciardi‐Castagnoli, P., Chan, A. S. Y., & Lim, T. S. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.611017 · Cited by 23
Metadata
- Authors
- Schmitz, R., Wright, G. W., Huang, D. W., Johnson, C. A., Phelan, J. D., Wang, J. Q., Roulland, S., Kasbekar, M., Young, R. M., Shaffer, A. L., Hodson, D. J., Xiao, W., Yu, X., Yang, Y., Zhao, H., Xu, W., Liu, X., Zhou, B., Du, W., Chan, W. C., Jaffe, E. S., Gascoyne, R. D., Connors, J. M., Campo, E., Lopez-Guillermo, A., Rosenwald, A., Ott, G., Delabie, J., Rimsza, L. M., Tay Kuang Wei, K., Zelenetz, A. D., Leonard, J. P., Bartlett, N. L., Tran, B., Shetty, J., Zhao, Y., Soppet, D. R., Pittaluga, S., Wilson, W. H., & Staudt, L. M.
- Affiliations
- National Cancer Institute (US)
- National Institutes of Health (US)
- City Of Hope National Medical Center (US)
- BC Cancer Agency (CA)
- From the Lymphoid Malignancies Branch (R.S., D.W.H., J.D.P., J.Q.W., S.R., M.K., R.M.Y., A.L.S., D.J.H., W. Xiao, X.Y., Y.Y., H.Z., W. Xu, W.H.W., L.M.S.), the Biometric Research Program, Division of Cancer Diagnosis and Treatment (G.W.W.), and the Laboratory of Pathology, Center for Cancer Research (E.S.J., S.P.), National Cancer Institute, and the Office of Intramural Research, Center for Information Technology (C.A.J., X.L., B.Z., W.D.), National Institutes of Health, Bethesda, and the Cancer...
- University of Würzburg (DE)
- Robert Bosch Hospital (DE)
- University Health Network (CA)
- Mayo Clinic (US)
- Memorial Sloan Kettering Cancer Center (US)
- Alliance for Clinical Trials in Oncology (US)
- Washington University in St. Louis (US)
- Frederick National Laboratory for Cancer Research (US)
- ORCID
- Schmitz, Roland
- Wright, George W.
- Huang, Da Wei
- Phelan, James D.
- Wang, James Q.
- Roulland, Sandrine
- Kasbekar, Monica
- Young, Ryan M.
- Shaffer, Arthur L.
- Hodson, Daniel J.
- Xiao, Wenming
- Yu, Xin
- Yang, Yandan
- Zhao, Hong
- Zhou, Bin
- Chan, Wing C.
- Jaffe, Elaine S.
- Gascoyne, Randy D.
- Connors, Joseph M.
- Rosenwald, Andreas
- Ott, German
- Delabie, Jan
- Rimsza, Lisa M.
- Zelenetz, Andrew D.
- Leonard, John P.
- Bartlett, Nancy L.
- Tran, Bao
- Shetty, Jyoti
- Zhao, Yongmei
- Pittaluga, Stefania
- Wilson, Wyndham H.
- Staudt, Louis M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-04-12
- Volume
- 378
- Issue
- 15
- Pages
- 1396-1407
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6010183
- OpenAlex
- W2797584152
- Cited by
- 2,241
- References
- 30
- Citations by year
- 2026: 193 · 2025: 271 · 2024: 320 · 2023: 339 · 2022: 317 · 2021: 302 · 2020: 250 · 2019: 191 · 2018: 53
- FWCI
- 153.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Apollo
- Funders
- National Cancer Institute Strategic Partnering to Evaluate Cancer Signatures (SPECS II) grant (5U01CA157581-05)
- Intramural Research Program of the NIH, National Cancer Institute
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Clinical Neurology › CNS Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
- Keywords
- diffuse large B-cell lymphoma, genetic subtypes, B cell receptor signaling, NOTCH1 mutation, NOTCH2 mutation, EZH2 mutation, BCL2 translocation, CD79B mutation, germinal center B-cell-like lymphoma, therapeutic vulnerabilities, precision medicine, survival outcomes
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Biopsy, Genotype, Humans, Mutation, Prognosis, Lymphoma, Large B-Cell, Diffuse, Sequence Analysis, DNA, Genetic Heterogeneity, Gene Expression Profiling, Epigenesis, Genetic, Kaplan-Meier Estimate, Transcriptome, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.